Fig. 3
CWP232291 inhibits the expression of β-catenin and survivin in prostate cancer cells. a Reporter assay for WNT/β-catenin signaling after treatment with (+) or without (−) WNT3a (100 ng/mL) and CWP232291 (PC3, 200 nM; DU145, 400 nM; LNCaP, 60 nM; 22Rv1, 70 nM) in cell cultures. Results are expressed as means ± SD of three independent experiments. *P < 0.05 by one-way ANOVA. b Cells were exposed to CWP232291 for 24 h. Lysates were analyzed by western blotting with β-catenin, survivin, and bcl-2 antibodies. Actin was used as a loading control. Scale bar, 100 μm. c Cells were exposed to CWP232291 for 24 h and then stained with DAPI (blue) or β-catenin (green). Images were captured using a fluorescence microscope (Olympus). d LNCaP and (E) 22Rv1 cells were treated with or without IC50 doses of CWP232291 for 24 h (LNCaP, 60 nM; 22Rv1, 70 nM). Relative mRNA levels of c-myc, cyclinD1, MMP-7, and annexin-2 were quantified by real-time PCR in prostate cancer cells